PBLA logo

Panbela Therapeutics, Inc. Common Stock


PBLA: Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.


Show PBLA Financials

Consumer Interest
SEC Filings

Recent trades of PBLA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by PBLA's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol Feb. 28, 2023
  • Patent Title: Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol Aug. 24, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of PBLA in WallStreetBets Daily Discussion


Recent insights relating to PBLA

CNBC Recommendations

Recent picks made for PBLA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PBLA

Corporate Flights

Flights by private jets registered to PBLA